Scope and Claims Analysis for US Patent 7,772,209 (Pemetrexed + Folic Acid + Methylmalonic Acid Lowering Agent) and the US Patent Landscape

US Patent 7,772,209 claims a chemotherapy-support regimen for pemetrexed disodium that pairs folic acid with a “methylmalonic acid lowering agent,” followed by pemetrexed disodium. In the US claims shown, the methylmalonic acid lowering agent is expressly limited to vitamin B12 and specific B12 forms (including hydroxycobalamin, cyanocobalamin, chlorocobalamin and related cobalamins). The independent method claim is structured around sequencing (B12 analog followed by pemetrexed) plus dosage/schedule limitations that are repeated across dependent claims, with an optional cisplatin co-administration branch.

What does US Patent 7,772,209 claim for pemetrexed disodium administration?

Core answer: It claims methods for administering pemetrexed disodium to a patient using folic acid plus a B12-type “methylmalonic acid lowering agent,” with defined dosing and scheduling options, optionally with cisplatin.

Claim architecture: independent method + dependent parameterization

Claim 1 (independent):
Administer folic acid (effective amount) and a methylmalonic acid lowering agent (selected from a closed list of B12/cobalamin forms), then administer pemetrexed disodium (effective amount).
Claims 2–4:
Narrow the methylmalonic acid lowering agent to vitamin B12, with intramuscular dosing ranges and a specific 1000 μg example.
Claims 5–7:
Add repeat schedule for vitamin B12 after initiation of pemetrexed and timing for folic acid relative to pemetrexed.
Claims 8–10:
Add oral folic acid dosage range and subranges.
Claims 11, 13, 22:
Optional add-on: cisplatin administration.
Claims 12–22:
A second independent-style method (“improved method”) reciting a combined parameter bundle: folic acid dose range, B12 dose range, then pemetrexed disodium; then optional cisplatin and further dependent refinements.

“Methylmalonic acid lowering agent” limitation is an enumerated B12 list

Claim 1 defines the methylmalonic acid lowering agent as a selection from:

vitamin B12
hydroxycobalamin
cyano-10-chlorocobalamin
aquocobalamin perchlorate
aquo-10-cobalamin perchlorate
azidocobalamin
cobalamin
cyanocobalamin
chlorocobalamin

That enumeration matters for claim scope: it is not a functional “any MMA-lowering agent” concept. It is a closed structural list of cobalamin/B12 species, constraining infringement and design-around targets.

How broad is claim 1 versus the “improved method” limitations in claims 12–22?

Core answer: Claim 1 is broader on dosing specifics (only “effective amount” for folic acid and B12 analog), while claims 12–22 impose concrete dosing windows and a defined improved parameter set.

Claim 1 scope: sequencing + closed agent list + “effective amount”

Claim 1 does not recite:

specific folic acid mg/μg amounts
specific IM injection quantities for B12
a specific folic acid lead time or window
a specific B12 repeat interval
It requires:
folic acid + one of the enumerated B12 forms, then pemetrexed disodium

This creates a “functional dose” zone: any folic acid and any cobalamin form from the list that is administered in an “effective amount” in combination with pemetrexed in the required sequence could fall within claim 1, even if dose falls outside later dependent numeric ranges.

Claims 12–22: narrower, parameter-bundled regimen

Claim 12 requires the regimen to include, in an “improvement comprises” structure:

(a) folic acid between 350 μg and 1000 μg
(b) vitamin B12 between 500 μg and 1500 μg, prior to pemetrexed
(c) pemetrexed disodium

That combination is a key narrowing step. It limits coverage to a particular dosing band and sequencing scheme for both folic acid and vitamin B12, and it is independent of cisplatin.

Dependent tightening: the patent’s “numerical claim spine”

Across claims 3–5, 8–10, and 14–21, the patent repeatedly locks in:

vitamin B12 IM dose: 500–1500 μg, and 1000 μg as a specific example
folic acid oral dose: 0.3–5 mg and subranges including 350–600 μg or 350–1000 μg
folic acid timing: 1–3 weeks prior and/or 1–24 hours prior
B12 repeat interval: every 6–12 weeks until pemetrexed discontinuation

This makes the patent’s practical enforceability hinge on real-world pemetrexed supportive-care schedules used in clinical practice and incorporated into labels, protocols, and institutional standing orders.

Which vitamin B12 forms are explicitly covered as “methylmalonic acid lowering agent”?

Core answer: The claims cover vitamin B12 and specified cobalamins, not just cyanocobalamin.

Enumerated B12/cobalamin forms (Claim 1)

vitamin B12 (general)
hydroxycobalamin
cyano-10-chlorocobalamin
aquocobalamin perchlorate
aquo-10-cobalamin perchlorate
azidocobalamin
cobalamin
cyanocobalamin
chlorocobalamin

Infringement relevance: closed list reduces “agent substitution” defenses

If a competitor uses an MMA-lowering agent that is not within this enumerated list, it may fall outside claim 1. If a competitor uses a covered B12 form but outside certain dosing schedules, claim 1 may still be implicated via “effective amount,” while dependent claims likely become harder to satisfy.

What dosing and sequencing windows are claimed for folic acid and vitamin B12?

Core answer: The patent recites both dosing bands and timing windows that can be matched against standard pemetrexed regimens.

Vitamin B12 dosing and administration form

IM injection is explicitly recited in claims 3–5 and 14–15.
Ranges:
- 500–1500 μg IM
- specific embodiment: 1000 μg IM

Folic acid dosing and oral administration

Oral folic acid:
- 0.3 mg to about 5 mg (Claim 8)
- 350–1000 μg (Claim 9)
- 350–600 μg (Claim 10)
- Additional restriction via claim 12: 350–1000 μg (Claim 12)

Folic acid timing relative to pemetrexed

Two timing alternatives appear in dependent claims:

1–3 weeks prior to the first pemetrexed administration (Claim 6 / Claim 19)
1–24 hours prior to pemetrexed (Claim 7 / Claim 20)

Vitamin B12 repeat schedule until pemetrexed discontinuation

Every 6–12 weeks following the vitamin B12 administration, until pemetrexed is discontinued (Claim 5 / Claim 21)

Cisplatin co-administration branch

Claims 11, 13, and 22 add cisplatin to the method.

Does US 7,772,209 cover pemetrexed + cisplatin supportive regimens?

Core answer: Yes, the claims explicitly allow cisplatin co-administration, but they do not require it.

How cisplatin fits in claim structure

In claim 1 and claims 2–10, cisplatin is optional only through dependent claim 11.
In claim 12, cisplatin becomes optional through dependent claim 13 and later dependent claim 22.
This structure matters because a method is still within claim 1 even without cisplatin, while dependent claims require cisplatin for those narrower method embodiments.

What is the likely practical scope for a “pemetrexed folic acid B12” regimen in the US?

Core answer: The patent is aimed at pemetrexed supportive care protocols that use folic acid and IM B12/cobalamin prior to each treatment cycle.

Claim mapping to real-world protocol design

The patent’s coverage likely tracks common regimen components:

folic acid supplementation (oral) pre-pemetrexed
B12 premedication (IM) with repeat dosing across the treatment course
pemetrexed disodium chemotherapy sequence
optional cisplatin combination

Where coverage is broadest (easier to meet)

Claim 1: “effective amount” + required sequencing + enumerated cobalamin list.
That makes it resilient to some dose variation, as long as a covered B12 form is used and “effective amount” is satisfied.

Where coverage is narrowest (harder to meet)

Claim 12: numeric band requirement for folic acid and vitamin B12 prior to pemetrexed.
Dependent claims add additional numeric precision, time windows, and repeat schedule parameters.

How would a generic or biosimilar competitor design around US 7,772,209?

Core answer: The main design-around levers are (i) avoiding the enumerated cobalamin list, (ii) altering dosing windows, (iii) altering administration timing windows, and (iv) altering sequence.

Agent substitution strategy: leave the enumerated “methylmalonic acid lowering agent” list

Because claim 1 enumerates cobalamins, using a non-enumerated MMA-lowering agent could avoid literal infringement for claim 1. However, claim construction and doctrine-of-equivalents arguments are separate issues not shown here.

Dosing/timing strategy: avoid “prior to first administration” windows and numeric bands

Claim 12 requires specific folic acid and B12 dose ranges.
Dependent claims require specific pre-treatment windows and repeat intervals. Protocol changes that move outside these bands and windows would likely reduce risk of meeting those dependent claims.

Sequence strategy

Claim 1 requires folic acid and B12 administration followed by pemetrexed disodium. If supportive agents are administered without matching the required sequence, risk shifts away from the claim.

What other patents typically surround pemetrexed supportive care, and how does this one fit?

Core answer: Pemetrexed supportive care patent landscapes usually include formulation, dosing regimens, and combination-therapy method claims. US 7,772,209 is a method-of-treatment patent focused on chemotherapy support with folic acid and B12/cobalamins.

Adjacent claim “clusters” in similar estates (non-exhaustive)

method-of-treatment claims: folic acid + B12 with pemetrexed
dosing regimen claims: specific timing and repeat intervals
combination claims: pemetrexed with cisplatin or other agents
formulation/administration device claims: less directly implicated by supportive-care regimen patents

This patent’s claim set is method-centric and built to be met by clinical practice patterns rather than manufacturing parameters.

Orange Book status, expiration timeline, and litigation risk for US 7,772,209

Core answer: No Orange Book listing, FDA regulatory status, expiration date, or litigation record is provided in the inputs for US 7,772,209. Without those case-specific data, a reliable exclusivity and Paragraph IV/biologics litigation assessment cannot be generated from the claim text alone.

Key claim-to-risk map for infringement and licensing leverage

Claim	What must be done	Risk driver for accused regimens	Main design-around lever
1	Folate + enumerated MMA-lowering (B12/cobalamin list) then pemetrexed	“Effective amount” and covered cobalamin forms make it broad	Use a non-enumerated MMA-lowering agent and/or avoid required sequencing
2	Use vitamin B12 (not other listed forms)	Narrower agent selection	Use another listed B12 form changes may still fall within list; outside list reduces risk
3–4	Vitamin B12 IM: 500–1500 μg; or 1000 μg example	Dose band matching	Alter IM dose outside numeric ranges and/or dosing schedule
5	Repeat B12 every 6–12 weeks until pemetrexed ends	Protocol schedule matching	Change interval outside 6–12 weeks and/or change repeat criteria
6–7	Folic acid timing: 1–3 weeks prior or 1–24 hours prior	Timing window matching	Shift folic lead-in and/or stop folic within windows
8–10, 12	Oral folic acid numeric ranges; improved method requires 350–1000 μg and B12 500–1500 μg	Numeric band matching for both agents	Change folic and/or B12 dosing outside required bands
11, 13, 22	Add cisplatin	Combination protocol matching	Omit cisplatin (if clinically acceptable)

Key Takeaways

US 7,772,209 claims pemetrexed supportive care using folic acid plus an enumerated set of B12/cobalamin “methylmalonic acid lowering agents,” with pemetrexed administered after the supplements.
Claim 1 is the broadest coverage hook because it uses “effective amount” rather than fixed doses, but it is still constrained by a closed list of B12/cobalamin species.
Claims 12–22 narrow the protected regimen to defined oral folic acid and IM vitamin B12 dose ranges, with additional timing windows and repeat intervals.
Cisplatin is optional in dependent claims; the core supportive-care coverage does not require cisplatin.

FAQs

Does US 7,772,209 require intramuscular vitamin B12 in every claim?
No. IM dosing is required in specific dependent claims (e.g., claims 3–5, 14–15), while claim 1 broadly requires a methylmalonic acid lowering agent from the enumerated B12 list.
Can a protocol using cyanocobalamin avoid claim 1?
Cyanocobalamin is explicitly listed as a covered methylmalonic acid lowering agent in claim 1, so avoiding depends on using an agent not in the enumerated set.
What is the strictest numeric requirement in the “improved method” claim set?
The “improved method” claim 12 requires folic acid between 350 μg and 1000 μg and vitamin B12 between 500 μg and 1500 μg prior to pemetrexed, before pemetrexed disodium administration.
Do the claims allow folic acid to be given only hours before pemetrexed?
Yes. Dependent claims include folic acid administered 1–24 hours prior to pemetrexed (claim 7 and claim 20).
Is cisplatin required to infringe US 7,772,209?
No. Cisplatin is optional via dependent claims (claims 11, 13, and 22). The independent method claim coverage does not depend on cisplatin.

References

Provided claim text for US Patent 7,772,209 (user-provided).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	359823	⤷ Start Trial
Australia	6968801	⤷ Start Trial
Cyprus	1107649	⤷ Start Trial
Germany	60127970	⤷ Start Trial
Denmark	1313508	⤷ Start Trial
European Patent Office	1313508	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,772,209

Summary for Patent: 7,772,209